Running Royalty. As consideration for the license under this Agreement, if a Licensed Product contains [***] or another compound that is specifically disclosed in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether Net Sales are achieved by Licensee or by a Sublicensee. For example, if Net Sales by Licensee in a territory are [***] dollars ($[***]), a royalty of [***] dollars ($[***]) will be due to Licensor. If Net Sales by any Sublicensee in a territory are [***] dollars, a royalty of [***] dollars will be due to Licensor, payable by Licensee. If a Licensed Product contains as its active principle a compound that is not specifically disclosed in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether Net Sales are achieved by Licensee or by a Sublicensee. Earned royalties shall accrue in each country, the period of time commencing on the date of the First Commercial Sale in that country and continuing until the later of (a) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale of such Licensed Product in such country, (b) ten (10) years from the date of the First Commercial Sale in that country, or (c) the expiration in that country of regulatory exclusivity that effectively bars the commercial sale of a generic version of a Licensed Product by a third party. Upon the occurrence in any given country of the later of events (a) through (c) in the preceding sentence, no further royalty shall accrue to Licensor for Net Sales in that country regardless of the amount of sales achieved in that country by Licensee or any Sublicensee.
Appears in 3 contracts
Samples: Exclusive License Agreement (Reata Pharmaceuticals Inc), Exclusive License Agreement, Exclusive License Agreement (Reata Pharmaceuticals Inc)
Running Royalty. As consideration for In addition to the license under Section 3.1 License Issue Fee, Licensee agrees to pay to UFRF as earned royalties a royalty calculated as a percentage of Net Sales in accordance with the terms and conditions of this Agreement, if . The royalty is deemed earned as of the earlier of: (i) the date the Licensed Product and/or Licensed Process is actually sold and paid for; (ii) the date an invoice is sent by Licensee; or (iii) the date a Licensed Product contains [***] or another compound that and/or Licensed Process is specifically disclosed transferred to a third party for any promotional reasons. The royalty shall remain fixed while this Agreement is in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay to Licensor an earned royalty effect at a rate of [***] percent (of Net Sales. In the event that licenses from third parties are required by Licensee in order to make, have made, use, sell, offer to sell or import any particular Licensed Product or Licensed Process, then the earned royalty which Licensee is obligated to pay UFRF under this Section 3.2 shall be reduced by [***]%] for each one dollar ($1.00) of Net Salesin royalties which Licensee is obligated to pay to third parties under such licenses, whether Net Sales are achieved by Licensee or by a Sublicensee. For examplefurther provided, if Net Sales by Licensee in a territory are however, that the royalties payable to UFRF under this Section 3.2 shall not be reduced to less than [***] dollars ($[***]), a royalty of [***] dollars ($[***]) will be due to Licensor. If the applicable Net Sales by any Sublicensee in a territory are [***] dollars, a royalty of [***] dollars will be due to Licensor, payable by LicenseeSales. If a Licensed Product contains as its active principle a compound that or Licensed Process is not specifically disclosed in one or more covered under another patent of UFRF, the rights to which have been licensed to Licensee by UFRF under any of the patents or patent applications listed in Exhibit Alicense agreements of the License Agreement Group, Licensee shall pay to Licensor an earned royalty and which license agreement calls for the payment of royalties at the rate of [***] percent ([***]%) of Net Sales, whether Net Sales are achieved by Licensee or by a Sublicensee. Earned duplicative royalties shall accrue in each country, for the period of time commencing on the date of the First Commercial Sale in that country and continuing until the later of (a) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale sales of such Licensed Product in or Licensed Process shall not be owed to UFRF by Licensee. Under such countrycircumstances, (b) ten (10) years from the date royalty calculation shall be made only once, even though the sale of the First Commercial Sale in that country, or (c) the expiration in that country of regulatory exclusivity that effectively bars the commercial sale of a generic version of a Licensed Product by a third party. Upon the occurrence in any given country of the later of events (a) through (c) in the preceding sentence, no further royalty shall accrue to Licensor for Net Sales in that country regardless of the amount of sales achieved in that country by Licensee or any SublicenseeLicensed Process may fall under more than one patent and more than one license agreement.
Appears in 2 contracts
Samples: Exclusive License Agreement, Exclusive License Agreement (Applied Genetic Technologies Corp)
Running Royalty. As consideration for the license under this Agreement, if a Licensed Product contains [***] or another compound that is specifically disclosed in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether on Net Sales are achieved by Licensee or by a Sublicensee. For example, if Net Sales by Licensee in a territory are [***] dollars ($[***]), as follows:
a. a royalty of [***] dollars ($[***]) will be due to Licensor. If of annual aggregate Net Sales by any Sublicensee in a territory are [***] dollars, of Licensed Products or Licensed Methods; and
b. a royalty of [***] dollars of annual aggregate Net Sales of Other Products. Royalties will be due paid within 30 days of the end of each calendar quarter; provided that, any running royalty payments arising from Net Sales by Sublicensees shall be payable within thirty (30) days after Licensee’s receipt of the relevant royalty payment from such Sublicensee. Notwithstanding the foregoing, non-payment of royalty payments by Sublicensee(s) to Licensor, payable Licensee shall not relieve Licensee from owing all amounts known by Licensee. If a Licensed Product contains as its active principle a compound that is not specifically disclosed in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay based on reasonable inquiry, to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether be due on Net Sales are achieved by Licensee or by a Sublicensee. such Sublicensees Earned royalties shall accrue in each country for the duration of Patent Rights in that country. For the avoidance of doubt should a product qualify as both an Other Product and as a Licensed Product or Licensed Method hereunder, Licensee shall only be required to pay one (1) royalty on such product, which royalty shall be the royalty rate applicable to Net Sales of Licensed Products or Licensed Methods. For avoidance of doubt, in the event Licensee terminates this Agreement prior to expiration of the Term of the Agreement as set forth in Article 3, the period of time commencing on the date of the First Commercial Sale in that country royalties due and continuing payable by Licensee pursuant to Section 4.3(b) shall survive until the later earlier of (ai) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale of such Licensed Product in such country, (b) ten (10) years from the date of the First Commercial Sale in that country, Target Patent Rights or (cii) the expiration in that country of regulatory exclusivity that effectively bars the commercial sale of a generic version of a Licensed Product by a third party. Upon the occurrence in any given country of the later of events (a) through (c) in the preceding sentenceSeptember 23, no further royalty shall accrue to Licensor for Net Sales in that country regardless of the amount of sales achieved in that country by Licensee or any Sublicensee2035.
Appears in 1 contract
Samples: Exclusive License Agreement (Yumanity Therapeutics, Inc.)